Baseline thyroid indices and the subsequent response to citalopram treatment, a pilot study
- PMID: 23533025
- PMCID: PMC3607150
- DOI: 10.1002/brb3.109
Baseline thyroid indices and the subsequent response to citalopram treatment, a pilot study
Abstract
The lack of reliable outcome predictors and the delayed onset of therapeutic response to antidepressants are among the clinical challenges in the treatment of depression. Identifying clinical correlates associated with antidepressant response would reduce symptom severity and morbidity for patients with depression. Twenty-three subjects with major depression were treated with citalopram 20 mg/day in a 6-week open trial and were also simultaneously randomized to either adjunctive triiodothyronine (T3) 25 μg BID (n = 7), pindolol 5 mg BID (n = 8), or placebo (n = 8). Baseline thyroid-stimulating hormone (TSH), FT4, FT3, and TT3 were measured for potential relationships to treatment response across groups. In males only, there was a significant inverse correlation between baseline free T4 and time to response (r = -0.7, P = 0.034). In both males and females across all treatment conditions, as measured by Kaplan-Meier (K-M) maintenance failure time, baseline TSH below the mean (1.5 ng/dL) was associated with a shorter time to response (50% reduction in Montgomery and Asberg Depression Rating Scale [MADRS] score) (χ(2) = 4.53, df = 1, P = 0.03). Patients with baseline TSH above the mean were less likely to reach full remission (MADRS ≤ 7) (χ(2) = 4.38, df = 1, P = 0.03). No significant differences between groups emerged in the mean response time. Baseline thyroid function, as measured by serum free T4 and TSH, may predict a patient's response time to antidepressant treatment with citalopram.
Keywords: Acceleration; antidepressant response; citalopram; free thyroxine; thyroid; thyroid-stimulating hormone; triiodothyronine.
Figures
References
-
- Abulseoud O, Sane N, Cozzolino A, Kiriakos L, Mehra V, Gitlin M, et al. Free T4 index and clinical outcome in patients with depression. J. Affect. Disord. 2007;100:271–277. - PubMed
-
- Altshuler LL, Bauer M, Frye MA, Gitlin MJ, Mintz J, Szuba MP, et al. Does thyroid supplementation accelerate tricyclic antidepressant response? A review and meta-analysis of the literature. Am. J. Psychiatry. 2001;158:1617–1622. - PubMed
-
- Amsterdam JD, Fava M, Maislin G, Rosenbaum J, Hornig-Rohan M. TRH stimulation test as a predictor of acute and long-term antidepressant response in major depression. J. Affect. Disord. 1996;38:165–172. - PubMed
-
- Baldwin DS, Stein DJ, Dolberg OT, Bandelow B. How long should a trial of escitalopram treatment be in patients with major depressive disorder, generalised anxiety disorder or social anxiety disorder? An exploration of the randomised controlled trial database. Hum. Psychopharmacol. 2009;24:269–275. - PubMed
-
- Bech P. Meta-analysis of placebo-controlled trials with mirtazapine using the core items of the Hamilton Depression Scale as evidence of a pure antidepressive effect in the short-term treatment of major depression. Int. J. Neuropsychopharmacol. 2001;4:337–345. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
